Trade Report: The Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) Given Average Recommendation of “Buy” from Analysts

The Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) Given Average Recommendation of “Buy” from Analysts

Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) has been assigned an average recommendation of “Buy” from the eight analysts that are currently covering the firm. Three analysts have rated the stock with a hold recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $87.61.

A number of brokerages have recently commented on EGRX. RBC Capital Markets reaffirmed an “outperform” rating and issued a $80.00 price target (up from $78.00) on shares of Eagle Pharmaceuticals in a research note on Thursday, September 22nd. Zacks Investment Research raised Eagle Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, September 20th. Mizuho upped their price target on Eagle Pharmaceuticals from $47.00 to $65.00 and gave the company a “neutral” rating in a research note on Tuesday, August 16th. TheStreet raised Eagle Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, August 9th. Finally, Royal Bank Of Canada reaffirmed a “buy” rating and issued a $78.00 price target on shares of Eagle Pharmaceuticals in a research note on Monday, June 13th.

Shares of Eagle Pharmaceuticals (NASDAQ:EGRX) traded up 1.74% during trading on Wednesday, reaching $70.34. 186,411 shares of the company traded hands. The stock has a market cap of $1.10 billion, a P/E ratio of 360.72 and a beta of 1.16. The stock’s 50 day moving average price is $63.02 and its 200-day moving average price is $48.34. Eagle Pharmaceuticals has a 12 month low of $33.02 and a 12 month high of $102.48.

Eagle Pharmaceuticals (NASDAQ:EGRX) last announced its quarterly earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.71 by $0.09. The company earned $40.90 million during the quarter, compared to analysts’ expectations of $43.55 million. Eagle Pharmaceuticals had a return on equity of 3.44% and a net margin of 3.45%. Eagle Pharmaceuticals’s revenue was up 581.7% on a year-over-year basis. During the same period in the prior year, the business posted ($0.53) EPS. On average, equities research analysts expect that Eagle Pharmaceuticals will post $3.21 EPS for the current fiscal year.

In other Eagle Pharmaceuticals news, major shareholder Proquest Investments Iv, L.P. sold 22,100 shares of the company’s stock in a transaction that occurred on Friday, September 30th. The stock was sold at an average price of $70.06, for a total transaction of $1,548,326.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 18.80% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in EGRX. PNC Financial Services Group Inc. increased its position in Eagle Pharmaceuticals by 2.9% in the second quarter. PNC Financial Services Group Inc. now owns 12,578 shares of the specialty pharmaceutical company’s stock worth $488,000 after buying an additional 349 shares during the period. Emerald Acquisition Ltd. bought a new stake in Eagle Pharmaceuticals during the second quarter valued at approximately $839,000. Swiss National Bank increased its stake in Eagle Pharmaceuticals by 10.2% in the second quarter. Swiss National Bank now owns 15,100 shares of the specialty pharmaceutical company’s stock valued at $586,000 after buying an additional 1,400 shares during the last quarter. Columbus Circle Investors bought a new stake in Eagle Pharmaceuticals during the second quarter valued at approximately $306,000. Finally, California State Teachers Retirement System increased its stake in Eagle Pharmaceuticals by 2.1% in the second quarter. California State Teachers Retirement System now owns 18,565 shares of the specialty pharmaceutical company’s stock valued at $720,000 after buying an additional 385 shares during the last quarter. 95.67% of the stock is owned by hedge funds and other institutional investors.

Related posts

Leave a Comment